Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

被引：0
|
作者：
P Hamberg
N Steeghs
W J Loos
D van de Biessen
M den Hollander
M Tascilar
J Verweij
H Gelderblom
S Sleijfer
机构：
[1] Erasmus University Medical Center Daniel Den Hoed Cancer Center,Department of Medical Oncology
[2] Leiden University Medical Center,Department of Medical Oncology
来源：
British Journal of Cancer | 2010年 / 102卷
关键词：
sunitinib; ifosfamide; pharmacokinetic; VEGF; drug-interaction; phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1699 / 1706
页数：7
相关论文
共 50 条
  • [41] Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
    Brell, Joanna M.
    Krishnamurthi, Smitha S.
    Rath, Linda
    Bokar, Joseph A.
    Savvides, Panayiotis
    Gibbons, Joseph
    Cooney, Matthew M.
    Meropol, Neal J.
    Ivy, Percy
    Dowlati, Afshin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (04) : 547 - 553
  • [42] A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
    Rini, Brian I.
    Garcia, Jorge A.
    Cooney, Matthew M.
    Elson, Paul
    Tyler, Allison
    Beatty, Kristi
    Bokar, Joseph
    Mekhail, Tarek
    Bukowski, R. M.
    Budd, G. Thomas
    Triozzi, Pierre
    Borden, Ernest
    Ivy, Percy
    Chen, Helen X.
    Dolwati, Afshin
    Dreicer, Robert
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6277 - 6283
  • [43] PHASE I, DOSE-FINDING STUDY OF SUNITINIB (SU) IN COMBINATION WITH IRINOTECAN (IR) IN PATIENTS WITH ADVANCED SOLID TUMOURS
    Boven, E.
    Massard, C.
    Armand, J. P.
    Tillier, C.
    Hartog, V.
    Brega, N. M.
    Contouriotis, A. M.
    Law, C. N. J.
    Soria, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 156 - 157
  • [44] Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies
    Villalona-Calero, MA
    Weiss, GR
    Burris, HA
    Kraynak, M
    Rodrigues, G
    Drengler, RL
    Eckhardt, SG
    Reigner, B
    Moczygemba, J
    Burger, HU
    Griffin, T
    Von Hoff, DD
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1915 - 1925
  • [45] Pharmacokinetics of ifosfamide are changed by combination with docetaxel - Results of a phase I pharmacologic study
    Schrijvers, D
    Pronk, L
    Highley, M
    Bruno, R
    Locci-Tonelli, D
    De Bruijn, E
    Van Oosterom, AT
    Verweij, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 358 - 363
  • [46] Phase I study of docetaxel plus ifosfamide in patients with advanced cancer
    Marx, G
    Lewis, C
    Hall, K
    Levi, J
    Ackland, S
    BRITISH JOURNAL OF CANCER, 2002, 87 (08) : 846 - 849
  • [47] Phase I study of docetaxel plus ifosfamide in patients with advanced cancer
    G Marx
    C Lewis
    K Hall
    J Levi
    S Ackland
    British Journal of Cancer, 2002, 87 : 846 - 849
  • [48] Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study
    Klaassen, U
    Harstrick, A
    Strumberg, D
    Wilke, H
    Seeber, S
    ANTI-CANCER DRUGS, 1998, 9 (04) : 359 - 361
  • [49] A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors
    Sweeney, C.
    Verschraegen, C.
    Chiorean, G.
    Lee, F.
    Jones, S.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
    C Kosmas
    N Tsavaris
    N Malamos
    N Stavroyianni
    A Gregoriou
    S Rokana
    A Polyzos
    British Journal of Cancer, 2003, 88 : 1168 - 1174
12345